Bolt Biotherapeutics financials
$3.60+4.04%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $7.7M | $7.7M | $7.9M | $5.7M | $1.3M |
| Gross profit | $7.7M | $7.7M | $7.9M | $5.7M | $1.3M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$36.1M | -$73.0M | -$76.2M | -$90.3M | -$92.8M |
| Net income | -$33.4M | -$63.1M | -$69.2M | -$88.1M | -$98.6M |
| Net margin | −433.7% | −820.8% | −878.6% | −1537.8% | −7824.7% |
| Diluted EPS | $-17.85 | $-33.06 | $-36.60 | $-47.20 | $-59.40 |
| EBITDA | -$33.3M | -$66.5M | -$74.3M | -$88.7M | -$91.6M |
| Operating cash flow | -$39.9M | -$61.3M | -$69.5M | -$76.5M | -$57.1M |
| Free cash flow | -$39.9M | -$61.3M | -$69.7M | -$78.5M | -$59.4M |
| Diluted shares | 1.9M | 1.9M | 1.9M | 1.9M | 1.7M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $11.7M | $7.2M | $10.8M | $9.2M | $27.4M |
| Short-term investments | $15.8M | $40.1M | $91.4M | $159.6M | $158.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $56.7M | $99.6M | $159.8M | $227.8M | $307.7M |
| Total liabilities | $30.2M | $42.4M | $47.0M | $56.3M | $57.6M |
| Shareholders' equity | $26.5M | $57.2M | $112.7M | $171.5M | $250.1M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology